U.S. Genomics’ DLA platform will be used to develop a test for infectious diseases.

BD (Becton, Dickinson and Company) made a $4.5 million equity investment in U.S. Genomics and entered into a collaboration to develop an infectious disease diagnostic platform.

The partnership will leverage U.S. Genomics’ DirectLinear Analysis (DLA) technology for the detection of infectious organisms in a single test.

U.S. Genomics reports that it has invested in excess of $50 million in DLA technology, which integrates labeling strategies, advanced microfluidics, and optical engineering. It enables the identification of pathogens by analyzing individual DNA molecules present in a clinical sample.

DLA has the potential to provide information such as which drugs a specific pathogen may be resistant to and which drugs could be used for most effective patient treatment, according to the companies.

This site uses Akismet to reduce spam. Learn how your comment data is processed.